Related Experiment Videos
Thrombocytopenia associated with etretinate therapy
1Department of Medicine, University of Hong Kong, Queen Mary Hospital.
Acta Haematologica
|January 1, 1988
Summary
A case study highlights that etretinate, a psoriasis treatment, may cause thrombocytopenia (low platelet count). Regular platelet count monitoring is advised for patients undergoing etretinate therapy.
Area of Science:
- Dermatology
- Hematology
Background:
- Psoriasis is a chronic autoimmune condition.
- Etretinate is a second-generation retinoid used for treating severe psoriasis.
Observation:
- A patient undergoing etretinate therapy for psoriasis developed thrombocytopenia.
- The clinical presentation suggested a causal link between etretinate and the observed low platelet count.
Findings:
- Etretinate therapy was identified as the likely cause of thrombocytopenia in this case.
- This adverse event underscores a potential hematological risk associated with etretinate.
Implications:
- Monitoring platelet counts in patients receiving etretinate is crucial for early detection of thrombocytopenia.
- This finding may inform clinical practice guidelines for psoriasis management and retinoid therapy.